Predictors of relapse in a fixed-dose, randomized, double-blind, 52-week relapse prevention trial of selegiline transdermal system

被引：0
|
作者：
Patkar, A. [1 ]
Jang, S. [1 ]
Jung, S. [1 ]
Pae, C. [1 ]
Jae, Y. [1 ]
Portland, K. [2 ]
机构：
[1] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC 27706 USA
[2] Dey Pharma LP, Med Affairs, Basking Ridge, NJ USA
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2012年 / 22卷
关键词：
D O I：
10.1016/S0924-977X(12)70380-2
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S254 / S254
页数：1
相关论文
共 50 条
  • [1] Predictors of relapse in patients with major depressive disorder in a 52-week, fixed dose, double blind, randomized trial of selegiline transdermal system (STS)
    Jang, Saeheon
    Jung, Sungwon
    Pae, Chiun
    Portland, Kimberly Blanchard
    Nelson, J. Craig
    Patkar, Ashwin A.
    JOURNAL OF AFFECTIVE DISORDERS, 2013, 151 (03) : 854 - 859
  • [2] Selegiline transdermal system in the prevention of relapse of major depressive disorder - A 52-week, double-blind, placebo-substitution, parallel-group clinical trial
    Amsterdam, Jay D.
    Bodkin, J. Alexander
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2006, 26 (06) : 579 - 586
  • [3] Effect of aripiprazole adjunctive to lamotrigine on manic and mixed subpopulations: 52-week, double-blind, randomised relapse prevention trial
    Fountoulakis, K. N.
    Rahman, Z.
    Fyans, P.
    Eudicone, J. M.
    Forbes, R. A.
    Baker, R. A.
    Carlson, B. X.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S438 - S438
  • [4] Effect of aripiprazole adjunctive to lithium or valproate on manic and mixed subpopulations: 52-week, double-blind, randomised relapse prevention trial
    Fountoulakis, K. N.
    Ammerman, D.
    Fyans, P.
    Marler, S. V.
    Forbes, R. A.
    Rahman, Z.
    Baker, R. A.
    Carlson, B. X.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S429 - S429
  • [5] Impact of fixed-dose combination Cal/BD foam on the work productivity of patients with psoriasis: results from the 52-week randomized, double-blind, PSO-LONG trial
    Guenther, L.
    Takhar, A.
    Megna, M.
    Sebastian, M.
    Nyholm, N.
    Thoning, H.
    Levin, L-A
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (07) : 1054 - 1063
  • [6] Probucol combined with valsartan in diabetic nephropathy: a 52-week, randomized, double-blind clinical trial
    Ye, Zhiming
    Zhang, Li
    Xiao, Zhenghua
    Wang, Li
    Cai, Dehong
    Li, Wangen
    Huang, Rui
    Liu, Shuangxin
    Liang, Xinling
    Wang, Wenjian
    Chen, Yuanhan
    Zhang, Bin
    Ma, Jianchao
    Feng, Zhonglin
    Li, Ruizhao
    Lin, Ting
    Liang, Yongzheng
    Shi, Wei
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (03): : 2161 - 2171
  • [7] A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse
    Beasley, CM
    Sutton, VK
    Hamilton, SH
    Walker, DJ
    Dossenbach, M
    Taylor, CC
    Alaka, KJ
    Bykowski, D
    Tollefson, GD
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (06) : 582 - 594
  • [8] Ziprasidone vs risperidone in schizophrenia: 52-week randomized, double-blind comparison
    Addington, D
    Pantelis, C
    Romano, SJ
    Murray, S
    SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 177 - 177
  • [9] Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial
    Brown, WV
    Bays, HE
    Hassman, DR
    McKenney, J
    Chitra, R
    Hutchinson, H
    Miller, E
    AMERICAN HEART JOURNAL, 2002, 144 (06) : 1036 - 1043
  • [10] Amlodipine/valsartan fixed-dose combination treatment in the management of hypertension: A double-blind, randomized trial
    Wang, Kang-Ling
    Yu, Wen-Chung
    Lu, Tse-Min
    Chen, Lung-Ching
    Leu, Hsin-Bang
    Chiang, Chern-En
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2020, 83 (10) : 900 - 905
12345